Compare CleanSpark Inc (CLSK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CleanSpark Inc vs Sanofi SA — how do they compare? CleanSpark Inc trades at $14.1 (market cap $3.45B), while Sanofi SA trades at $43.67 (market cap $102.91B). The key difference: Sanofi SA is far larger — about 29.8× CleanSpark Inc's market cap, and Sanofi SA pays a 5.6% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| CLSK | SNY | |
|---|---|---|
Market Cap | $3.45B | $102.91B |
Sector | Technology | Health |
52-Week High | $23.20 | $52.34 |
52-Week Low | $8.18 | $41.33 |
Enterprise Value | $4.31B | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CleanSpark (CLSK) trades at $12.36, down 3.81% today, with a bearish technical signal and recent earnings misses. The company reported a net loss margin of -67.66% for 2026 but announced a transformative $6.6 billion 20-year AI data center lease, shifting focus from Bitcoin mining to high-performance computing. Analyst consensus remains unanimously bullish with a $21.43 price target, highlighting growth potential despite current profitability challenges.
The outlook balances high growth potential from the AI pivot against significant execution risks and persistent losses. Near-term volatility is expected as the market assesses the company's ability to monetize new contracts and achieve sustainable profitability. The stock presents a high-risk, high-reward opportunity dependent on successful business model transition.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
